Company Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy.
It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
| Country | France |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Daniel Tassé |
Contact Details
Address: Bâtiment IRO, 107 Av. de la République Châtillon, 92320 France | |
| Phone | 33 1 55 42 78 78 |
| Website | dbv-technologies.com |
Stock Details
| Ticker Symbol | DBVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001613780 |
| CUSIP Number | 23306J101 |
| ISIN Number | US23306J1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel Tassé | Chief Executive Officer and Director |
| Virginie Simone Jeanine Verrechia Boucinha M.B.A. | Chief Financial Officer and Principal Accounting Officer |
| Dr. Pharis Mohideen | Chief Medical Officer |
| Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer |
| Katie Matthews | Investor Relations Officer |
| Michele F. Robertson | Chief Legal Officer |
| Caroline Daniere | Chief Human Resources Officer and Chief of Staff |
| Dr. Wence Agbotounou | Chief Clinical Trial Officer and Senior Vice President |
| Edward P. Jordan M.B.A. | Senior Vice President of Commercial Operations North America |
| Alan Kerr | Senior Vice President and Head of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | 10-K/A | [Amend] Annual report |
| Apr 17, 2025 | D | Notice of Exempt Offering of Securities |
| Apr 14, 2025 | SCHEDULE 13G | Filing |
| Apr 11, 2025 | SCHEDULE 13G | Filing |
| Apr 11, 2025 | 10-K | Annual Report |
| Apr 8, 2025 | SCHEDULE 13G | Filing |
| Apr 7, 2025 | SCHEDULE 13D/A | Filing |
| Mar 31, 2025 | SCHEDULE 13D/A | Filing |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 31, 2025 | 8-K | Current Report |